Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$16.83 – $41.14
100% from low
Sector
Biotechnology
P/S (TTM)
4.7
EV / FCF (TTM)
139
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
www.apellis.comNo one on the platform currently holds APLS.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 935,958 | $37.7M |
| Execution date | Ratio |
|---|---|
| 2004-03-19 | 1-for-200reverse |
No one on the platform has traded APLS yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.2% | — | — | — | ||
| Rev. Growth % | 28.5% | 32.0% | ||||
| Profit Margin % | 2.2% | -428.5% | ||||
| Free Cash Flow Margin % | 4.5% | -337.6% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $871M | -13.3% | $-1.03 | $-1.97–$-0.34 | — | 8 |
| 2027 | $1.0B | +17.8% | $-0.07 | $-0.33–$0.11 | — | 10 |
| 2028 | $1.3B | +23.0% | $1.26 | $-0.88–$7.48 | 32.5× | 12 |
| 2029 | $1.4B | +8.3% | $1.56 | $1.36–$1.80 | 26.2× | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | $-0.38 | $0.15 | +139.5% |
| 2026-02-24 | $-0.39 | $-0.47 | -20.5% |
| 2025-10-30 | $1.03 | $1.67 | +62.1% |
| 2025-07-31 | $-0.44 | $-0.33 | +25.0% |
| 2025-05-07 | $-0.36 | $-0.74 | -105.6% |
| 2025-02-28 | $-0.37 | $-0.29 | +21.6% |
| 2024-11-05 | $-0.32 | $-0.46 | -43.8% |
| 2024-08-01 | $-0.33 |
| $-0.28 |
| +15.2% |
| +0.00% |
| $5.6B |
| — |
| CPRXCatalyst Pharmaceuticals, Inc. | $31.49 | +0.00% | $3.9B | — |
| IDYAIDEAYA Biosciences, Inc. | $37.66 | -0.97% | $3.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
$CAPR Surface-level retail panics during artificial pullbacks, but deep balance-sheet math reveals how short suppression sets up asymmetric surges off the absolute bottom. Look at historical re-rate models like $APLS, $SLNO, and $CRNX—each suffered brutal short-selling cycles, statistical noise, and regulatory fear before their underlying platforms were re-valued and multiplied massive orders of magnitude directly from their trough lows. Understanding true structural catalysts over daily retail chatter is how you capture generational biotech runs. 🧬💎 🚫 DO NOT FOLLOW ME. I post for my own science log and balance sheet math, not retail cheerleading. If you want hype, go buy a meme coin.
View on StockTwits ↗
@Thaigrlsrk nah this poster is legit . Was with them in $APLS shared good insight . Ultimately led to buy out.
View on StockTwits ↗Another takeaway from $SCPH & a few others in the past year for that matter $DAWN $APLS $SLNO Forced selling taking place before buyout on the cheap (need an artificially high premium) $XBI
View on StockTwits ↗
@Timefortendies77 $PRVB $APLS $CCXI $CTIC Then good things happened
View on StockTwits ↗
$ABVX reminds me of $APLS , another company whose french CEO thought his company deserved a higher buyout price, only for the stock to tank on lower pharma sales due to safety worries. Could have sold for over $100/share, but eventually sold for something like $40ISH a share a couple years later after poor sales. French always think they’re better..
View on StockTwits ↗
$NOK this is how market buils narrative, hypes, unloades bags. and triggers Stop losses. Story may be intact but imagine how many stop losses , margin calls, account wiped out. These stocks may go back to ath bit how many van stomach such losses. Not many $APLS $IREN
View on StockTwits ↗@Turribull ok let’s go here show me or cite me where you have made calls on stocks and made money, I will state mine $APLS $AKRO $TERN
View on StockTwits ↗@Ilovemuffins1 @HarryScrotmmm I'm not speaking for everyone on the board and have done extremely well and you can look me up on all the BO's I have had this year alone- I'll name some for you $TERNS-$APLS-$AKRO tell me what you got?
View on StockTwits ↗
$OTLK $EYPT $APLS What a strong week for $OTLK 🚀🔥 "The Office of New Drugs (OND) concluded that substantial evidence of effectiveness has been established and that additional adequate and well-controlled clinical studies are not required for approval of ONS-5010." EU approval ✅UK approval ✅Commercial launch underway in Germany and the UK ✅FDA appeal confirmed efficacy ✅BLA resubmission announced June 1st and accepted as a Class 1 review (~60 days) ✅Final FDA decision pending ⏳ Connect the dots. The picture is getting pretty clear. 👀🚀 This story keeps getting stronger.💪
View on StockTwits ↗$IMMX nice data with 95% CR rate and no relapses, should easily digest the $150M offering Hat tip to @Sanctuary_Bio, believe this is one of his Winners (on Coffee Call, mentioned you chose it over $APLS and it's 3x'd from Q4 lows)
View on StockTwits ↗
$APLS Good move here. I have cut 75% of it, and I'm keeping the other 25% in my long-term. I don't think we're going to be losing anything here, but it might as well take a little bit of profit as we continue to ride.
View on StockTwits ↗
$APLS Got them CVRs and $41/share. Paid in full. It’s been real gang, fade ‘em.
View on StockTwits ↗$BIIB completes $APLS acquisition ... next neph target to go?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.